SCHEMBL24117930

SCHEMBL24117930

C=C(CCNC(=O)c1ccc(C)c(Cl)c1)[C@H](C)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HTR1E P28566 2/20 0.47
▸ S1PR3 Q99500 2/20 0.47
▸ POLB P06746 3/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ IDO1 P14902 2/20 0.45
▸ GAA P10253 1/20 0.43
▸ GCG P01275 1/20 0.42
▸ TP53 P04637 2/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24118259 0.92 POLB (0.44) CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2
SCHEMBL24118244 0.90 ALDH1A1 (0.51) SMN1; SMN2MEN1KMT2AMAPTPOLB
SCHEMBL24118064 0.89 IDO1 (0.46) SMN1; SMN2RAB9AMEN1KMT2APOLB
SCHEMBL24118073 0.88 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2RAB9A
SCHEMBL24118311 0.88 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2RAB9A
SCHEMBL24117949 0.87 IDO1 (0.53) MEN1KMT2APOLBALDH1A1IDO1
SCHEMBL24118086 0.86 IDO1 (0.42) MEN1KMT2AS1PR3POLBALDH1A1
SCHEMBL24118272 0.84 MEN1 (0.44) CYP1A2CYP2C9CYP2C19SMN1; SMN2MEN1
SCHEMBL24118062 0.83 IDO1 (0.54) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL24118616 0.83 NAMPT (0.41) SMN1; SMN2MEN1KMT2AMAPTS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 CYP1A2 164/4885CYP3A4 1135/4885CYP2C9 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback